The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids
Official Title: A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of TAK-385 10, 20, and 40 mg (p.o.) in the Treatment of Uterine Fibroids
Study ID: NCT01452659
Brief Summary: The purpose of this study is to determine the efficacy and safety of TAK-385, once daily (QD), for 12 weeks in women with uterine fibroids.
Detailed Description: This study is a Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled for evaluation of the efficacy and safety of TAK-385 10, 20, and 40 mg (p.o.) following once daily administration for 12 weeks in women with uterine fibroids.
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
, Chiba-shi, Chiba, Japan
, Itchihara-shi, Chiba, Japan
, Matsuno-shi, Chiba, Japan
, Matsuyama-shi, Ehime, Japan
, Nihama-shi, Ehime, Japan
, Fukui-shi, Fukui, Japan
, Fukuoka-shi, Fukuoka, Japan
, Iizuka-shi, Fukuoka, Japan
, Yanagigawa-shi, Fukuoka, Japan
, Mebashi-shi, Gunma, Japan
, Ebetsu-shi, Hokkaido, Japan
, Sapporo-shi, Hokkaido, Japan
, Amagasaki-shi, Hyogo, Japan
, Kobe-shi, Hyogo, Japan
, Kamakura-shi, Kanagawa, Japan
, Yokohama-shi, Kanagawa, Japan
, Oita-shi, Oita, Japan
, Ibaraki-shi, Osaka, Japan
, Osaka-shi, Osaka, Japan
, Sakai-shi, Osaka, Japan
, Tondabayashi-shi, Osaka, Japan
, Chuo-ku, Tokyo, Japan
, Itabashi-ku, Tokyo, Japan
, Setagaya-ku, Tokyo, Japan
, Shinagawa-ku, Tokyo, Japan
, Suginami-ku, Tokyo, Japan
, Toyama-shi, Toyama, Japan
Name: Senior Director
Affiliation: Takeda
Role: STUDY_DIRECTOR